First Page | Document Content | |
---|---|---|
Antidotes Chelating agents Deferiprone Transfusion hemosiderosis Beta-thalassemia Iron overload Myelodysplastic syndrome Thalassemia Deferoxamine Medicine Health Chemistry | oncologic drugs advisory committee briefing document sep[removed]Add to Reading ListSource URL: www.fda.govDownload Document from Source WebsiteFile Size: 1,06 MBShare Document on Facebook |
Preventability of serious transfusion reactions Martin Schipperus Jo WiersumOsselton Anita van Tilborgh Pauline ZijlkerDocID: 1aRsK - View Document | |
Medical Services Advisory Committee Public Summary DocumentDocID: 14Ow3 - View Document | |
DOCX DocumentDocID: 14Iww - View Document | |
Microsoft Word - M2M - Att A - PSD[removed]Liver Iron R2-MRI @[removed]members endorsed minutes.docDocID: UiMV - View Document | |
Medical Services Advisory Committee Public Summary DocumentDocID: TBM4 - View Document |